Lilly(US:LLY) ZACKS·2024-06-26 22:50Company Overview - Eli Lilly (LLY) closed at $901.26, with a -0.37% movement compared to the previous day, lagging behind the S&P 500's daily gain of 0.16% [1] - Over the past month, Eli Lilly's shares appreciated by 11.98%, outperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% [1] Financial Performance - Upcoming earnings per share (EPS) for Eli Lilly are projected to be $2.65, reflecting a 25.59% increase from the same quarter last year, with revenue anticipated at $9.8 billion, indicating a 17.96% upward movement from the same quarter last year [1] - For the full year, Zacks Consensus Estimates project earnings of $13.61 per share and revenue of $42.86 billion, demonstrating changes of +115.35% and +25.61% from the preceding year [2] Analyst Estimates and Stock Performance - Recent adjustments to analyst estimates for Eli Lilly are significant, as positive revisions typically indicate a favorable business outlook [2] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Eli Lilly as 3 (Hold) [3] - Within the past 30 days, the consensus EPS projection has moved 0.04% higher [3] Valuation Metrics - Eli Lilly is trading at a Forward P/E ratio of 66.46, which is a premium compared to the average Forward P/E of 14.79 for its industry [3] - The company has a PEG ratio of 1.99, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.82 [3] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a current Zacks Industry Rank of 85, placing it in the top 34% of all industries [4] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]